Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Weekly Docetaxel in Elderly Advanced NSCLC
NCT00541099Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jan 2008
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Survival Rate at 6 Months. Started Jan 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00541099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541099.